CAT/DRC royalty agreement
April 30 2002 - 12:00PM
UK Regulatory
RNS Number:3207V
Cambridge Antibody Tech Group PLC
30 April 2002
02/CAT/18
Not for release in Australia, Japan and the Republic of Ireland
Page 1 of 1
FOR IMMEDIATE RELEASE
16:00 GMT, 11:00 EST Tuesday 30 April 2002
For Further Information Contact:
Cambridge Antibody Technology Weber Shandwick Square Mile (Europe)
Tel: +44 (0) 1763 263 233 Tel: +44 (0) 20 7950 2800
John Aston, Finance Director Kevin Smith
Rowena Gardner, Head of Corporate Graham Herring
Communications
BMC Communications/The Trout Group (USA)
Tel: 001 212 477 9007
Brad Miles, ext 17 (media)
Brandon Lewis, ext.15 (investors)
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC
TERMINATES ROYALTY AGREEMENT WITH
DRUG ROYALTY CORPORATION INC.
Melbourn, UK and Toronto, Canada... Following Inwest Investment Ltd. acquiring
control of Drug Royalty Corporation Inc. ("DRC") (TSE: DRI), as announced by DRC
today, Cambridge Antibody Technology Group plc ("CAT") (LSE: CAT; NASDAQ: CATG)
and Cambridge Antibody Technology Limited ("CAT Limited") have today provided
written notice to DRC to terminate CAT Limited's royalty agreement with DRC (the
"Royalty Agreement"). In accordance with the terms of the Royalty Agreement, as
amended by CAT, CAT Limited and DRC on 16 January 2002 in connection with CAT's
offer to acquire all of the outstanding common shares of DRC, CAT has elected to
pay the C$14 million termination payment to DRC through the allotment of 463,818
CAT ordinary shares of 10 pence each (the "Shares").
Application has been made to the UK Listing Authority for the admission of the
Shares to the Official List, and to the London Stock Exchange for these
securities to be admitted to trading.
-ENDS-
This information is provided by RNS
The company news service from the London Stock Exchange
Catco Reinsurance Opport... (LSE:CAT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Catco Reinsurance Opport... (LSE:CAT)
Historical Stock Chart
From Jul 2023 to Jul 2024